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Background
A cohort of patients participating in a multicentric, mul-
tinational phase III trial to assess the efficacy and safety
of abatacept in juvenile idiopathic arthritis (JIA) were
discontinued from the study due to administrative
reasons.
Aim
To assess long term efficacy and monitor clinical follow
up after the sudden removal of abatacept.
Methods
Patients in the open arm of the trial, receiving 10mg/kg
monthly infusions of abatacept were followed for 4 years
after its suspension. Outcome measures included clinical
remission and disease control without biologics.
Results
Eight patients (7M/1F) with mean age of 16.5 years
(range 13-19years) and disease duration of 8,6years
(range 1,5-13years) were followed. All patients had poly-
articular involvement only partially responsive to metho-
trexate (extended oligoarticular (OE)-3, polyarticular
Rheumatoid factor IgM negative (Poly)-2, systemic onset
(SoJIA)-3). Concurrent therapies, maintained after the
abatacept trial included NSAIDS, Methotrexate (8/8)
and low dose steroids (3/8).
All patients met the ACRpedi30 criteria, 5 of which
(OE and Poly) were either in remission (2/8) or had
marked improvement (1or 2 active joints). After 12
months of follow-up, all OE patients had inactive dis-
ease, as well as one Poly (4/8). Subsequently, 1of the OE
and the other Poly flared, with etanercept being intro-
duced at 27 and 29months of follow-up, respectively; 3
patients currently remain in full remission after 4 years
(2 OE, 1 poly).
SoJIA patients maintained active disease, requiring
biologic therapy (mean 18months).
Conclusion
Although it’s a small cohort, this study suggests that
abatacept may induce long term remission in polyarticu-
lar JIA patients, especially EO and Poly subtypes. Similar
results were not observed in SoJIA patients.
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